The effect of chlorhexidine on Acinetobacter baumanii in intensive care units

Michel F. Martinez-Resendez¹, Flora Cruz-Lópezb, Natalia Gaona-Chávez¹, Adrián Camacho-Ortiz¹, Roberto Mercado-Longoria¹, Samantha Flores-Treviño¹, Paola Bocanegra-Ibarías¹, Elvira Garza-González*²

¹Department of Internal Medicine, University Hospital ‘Dr. José Eleuterio González’, Autonomous University of Nuevo Leon, Monterrey, Nue vo León, Mexico
²Department of Pharmaceutical Biological Chemistry, School of Chemistry, Autonomous University of Nuevo Leon, San Nicolas de los Garza, Nuevo León, Mexico
³Department of Biochemistry and Molecular Medicine, School of Medicine, University Hospital ‘Dr. José Eleuterio González’, Autonomous University of Nuevo Leon, Monterrey, Nue vo León, Mexico

Received: November 2020, Accepted: December 2021

ABSTRACT

Background and Objectives: Measures to prevent the emergence of hospital-acquired infections (HAIs) include a daily bath with chlorhexidine gluconate (CHG). The aim of this study was to determine the effect of patients bathing daily with CHG on the bacterial colonization on patient surfaces, environmental surrounding areas, and attending healthcare workers (HCWs).

Materials and Methods: Patients were randomized by a 1:1 in two groups. Patients in group 1 were bathed daily with CHG; patients in group 2 were bathed with a placebo. Microbiological sampling of patients, environment, and HCWs were carried out on days 0, 3, and 10. The clonal relatedness of selected isolates collected was determined through pulsed-field gel electrophoresis. Clinical and demographic data were obtained from medical files.

Results: Thirty-three patients were included (18 in group 1 and 15 in group 2). The more common species was Acinetobacter baumanii (n=144), followed by Klebsiella pneumoniae (n=81). A. baumanii was isolated more frequently on environmental surfaces in group 2 than group 1 (day 0 vs. day 3 vs. day 10; p = 0.0388). Twelve clones of A. baumanii were detected, with predominant clone A detected in patients and environmental surfaces. No pathogens were detected in HCWs.

Conclusion: Our data support that CHG bathing decreases A. baumanii surviving on the environmental surfaces of critically ill patients.

Keywords: Infection disease transmission; Chlorhexidine; Decontamination; Acinetobacter baumanii; Gram-negative bacteria

INTRODUCTION

Hospital-acquired infections (HAIs) cause significant morbidity and mortality in hospitalized patients (1), primarily those considered to be critically ill. For this reason, the study and control of HAIs have been deeply examined, with particular emphasis on epidemiological surveillance methods (2).

*Corresponding author: Elvira Garza-González, Ph.D, Department of Biochemistry and Molecular Medicine, School of Medicine, University Hospital ‘Dr. José Eleuterio González’, Autonomous University of Nuevo Leon, Monterrey, Nue vo León, Mexico. Tel: +52-81-83294173 Fax: +52-81-83294050 Email: elvira_garza_gzz@yahoo.com
About 25% of all HAIs develop in critically ill patients. This population is associated with several risk factors for these infections, including the use of invasive devices, the improper use of broad-spectrum antibiotics, as well as prolonged hospital stay (3). Furthermore, almost 40% of HAIs are caused by multidrug-resistant microorganisms, most of which are grouped by the acronym ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter cloacae) (1, 4, 5).

Measures to prevent the emergence of HAIs include a daily bath with chlorhexidine gluconate (CHG), which has been shown to reduce overall infection rates (6-8). In addition, previous studies have demonstrated that patients bathed using the traditional method had a higher risk of colonization by Gram-negative bacteria than those who bathed with CHG (6, 9).

To date, limited studies have evaluated whether the decrease in HAIs in critically ill patients bathed with CHG is associated with less colonization on their skin, in their immediate environment, and among healthcare personnel.

This study aimed to determine the effect of patients bathing daily with CHG on the colonization of the ESKAPE group on patient surfaces, environmental surrounding areas, and attending healthcare workers (HCWs).

MATERIALS AND METHODS

Study setting. The study was conducted at the University Hospital "Dr. José Eleuterio González", a third-level hospital with 600 beds in Monterrey, Mexico. This hospital has two intensive care units (ICU) for adults: one with 9 beds, surgical, and 11 medical beds. Both ICUs have approximately 500 hospitalizations per year.

Study design and criteria for inclusion, exclusion, and elimination. This was a prospective, experimental, randomized, double-blind study. All patients admitted to ICU with less than 48 h of hospital stay were included. Patients were excluded when they met one of the following criteria: younger than 18 years, pregnant, burns on more than 20% of total body surface area, or history of a CHG allergy. Patients with an adverse reaction to CHG, defined as the appearance of rash or pruritus, were eliminated. An established hand hygiene program was continued throughout the study.

Ethics approval. This protocol was approved by the Ethical Committee in Investigation at the School of Medicine, Autonomous University of Nuevo León (IF16-00003). Informed consent was requested from patients, patients’ relatives, and HCWs who agreed to participate in the study.

Randomization and intervention. Patients were randomized by a 1:1 closed envelope method and separated into two bath groups by a person outside the study. Patients assigned to group 1 were bathed daily with 2% CHG-impregnated wipes (Chlorhexi-Wipes One Step; G70 Antisepsis, Leon, Mexico), and hair was washed with no-rinse 0.12% CHG foam shampoo (Chlorhexidine Shampoo One Step; G70 Antisepsis) in addition to a 0.12% chlorhexidine hydrochloride oral solution. CHG products were used according to the supplier’s specifications.

Patients assigned to group 2 were bathed daily with towels made of the same components as the CHG wipes but without CHG, and standard shampoo without CHG was used to wash the scalp. Products for body and hair wash had the same labels, color, and smell as the CHG products. Baths were initiated from the day of admission until discharge from the ICU.

Decontamination procedures were daily done according to hospital protocols using 0.5% sodium hypochlorite impregnated microfibers. Between patients, an intensive cleaning process, including walls and ceiling, was undertaken.

Sampling of patients, environment, and health care workers. Sampling was carried out on days 0, 3, and 10 using the swabbing method as previously described (Williamson-Kligman 24 and HMP Protocol #07-001, version number 12.0) with a few modifications.

For environmental surfaces (bed rails, ventilators, and tables), a delimitation of an approximate area of 3 cm² was made for sampling. Then, 1 mL non-ionized solution was applied, and the area was gently scraped with a sterile cotton swab.

Nasal, cubital fossa, retro auricular region, and anorectal region samples from patients and palms and nasal samples of HCWs were obtained by rubbing and rotating the swab moistened with sterile SCF-1 buf-
fer (50 mM Tris buffer, 1 mM EDTA, 0.5% Tween 20) for 30 s on each site. One swab for each site was used. All samples were placed directly in agar plates.

**Microbiological methods.** Cultures were processed by standard methods. Samples were cultured on 5% blood agar and eosin-methylene blue agar. All plates were incubated at 37°C for 48 h. All isolates were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry system (Bruker Daltonics, Billerica, MA).

**Clonal relatedness.** The clonal relatedness of isolates collected was determined through pulsed-field gel electrophoresis (PFGE) on representative isolates (10, 11). Tenover criteria were used for interpretation using the Jaccard coefficient (10). SPSS version 21 was used for analysis (IBM Corp., Amonk, NY).

**Data collection.** Clinical and demographic data were obtained from medical files. Retrieved data included age, gender, length of stay, vital signs, urinary output, laboratory, and outcome. In addition, the following severity scores were used: acute physiology and chronic health evaluation (APACHE) II, Glasgow coma scale, simplified acute physiology score (SAPS) II, and Kirby index (PaO2/FiO2).

**Statistical analysis.** Continuous variables were analyzed as the means and standard deviation. For categorical variables, percentages and frequencies were used. Numerical variables were compared with Student’s t-test or with the Wilcoxon test. Categorical variables were analyzed using the chi-square test or Fisher’s exact test. Statistical analysis was performed with SPSS version 21.

**RESULTS**

**Study population and clinical data.** A total of 1,743 patients were admitted to the ICU from September 2017 to September 2019, and 63 met the inclusion criteria. From these patients, 30 were excluded from the analysis: 8 died, and 22 were transferred outside the ICU before the second swabbing.

Thirty-three patients were included (18 in group 1 and 15 in group 2). Both groups were paired among clinical, laboratory, and severity scores data. The median length of stay was 11 days (IQR, 6.0-15.2) in group 1 and 12 days (IQR, 8.0–19.0) in group 2. Both groups had more surgical patients than medical patients (66.7% vs. 33.3% in group 1 and 60% vs. 40% in group 2, respectively) (Table 1). In total, 33 nurses were sampled.

Three deaths were reported in group 1 (due to abdominal sepsis, meningitis, and cranial trauma) and one in group 2 (due to epidural hematoma). In group 1, 10 (55.5%) patients presented HAIs; 9 ventilator-associated pneumonia (VAP) (A. baumannii, n=6; K. pneumoniae, n=2; P. aeruginosa, n=1), and one urinary tract infection (P. aeruginosa). In group 2, 12 (80.0%) patients presented HAIs; 10 VAP (A. baumannii, n=5; K. pneumoniae, 4; and P. aeruginosa, 1); 1 catheter line-associated bloodstream infection (K. pneumoniae) and one surgical site infection (P. aeruginosa).

**Microbiology data.** Most isolates were Gram-negative bacilli species (354 Gram-negative and 82 Gram-positive), including A. baumannii (n = 144), K. pneumoniae (n= 81), and P. aeruginosa (n = 20), both from the patient’s body surfaces and from the environment. None of these pathogens were detected in HCWs. Other species of the ESKAPE group were E. cloacae (n = 44), Escherichia coli (n = 40), S. aureus (n = 14), and E. faecium (n = 14).

Other non-ESKAPE potential pathogens detected were Enterococcus faecalis (n = 54), Klebsiella aerogenes (n = 9), Stenotrophomonas maltophilia (n = 4), Klebsiella oxytoca (n = 3), Serratia marcescens (n = 2), Proteus mirabilis, Morganella morgani, Citrobacter koseri Citrobacter freundii, Pantoea calida, Pantoea septica, and Achromobacter insolitus (n = 1 from each).

For A. baumannii, group 2 exhibited more isolates on environmental surfaces (bedrails, worktables, and ventilators) than group 1 (day 0 vs. day 3 vs. day 10; p = 0.038). No differences were detected for K. pneumoniae and P. aeruginosa or other members of the ESKAPE group. When A. baumannii, K. pneumoniae, and P. aeruginosa bacilli were combined, group 2 had a higher number of isolates from patient bedrails than group 1 (day 0 vs. day 3 vs. day 10; p = 0.097). However, these findings were not statistically significant (Table 2). A total of 231 surfaces related to each patient included were sampled at day day 0; A. baumannii and K. pneumoniae rates colonization on sampled surfaces were 68/231 and 34/231, respectively at day 0 (before bath application).

**Clonal diversity.** Randomly selected most common species A. baumannii and K. pneumoniae isolates (in-


### Table 1. Clinical and demographic characteristics of the study population

| Demographic                          | CHG (n = 18) | No CHG (n = 15) | p value |
|--------------------------------------|--------------|----------------|---------|
| Demographic                          |              |                |         |
| Age, median (IQR)                    | 40.5 (25.2-56.0) | 43.0 (37.0-53.0) | 0.468   |
| Male, n (%)                          | 13 (72.2)    | 8 (53.3)       | 0.261   |
| Length of stay, days, median (IQR)   | 11.0 (6.0-15.2) | 12.0 (8.0-19.0) | 0.318   |
| Treatment                            |              |                |         |
| Medical, n (%)                       | 6 (33.3)     | 6 (40.0)       | 0.691   |
| Surgical, n (%)                      | 12 (66.7)    | 9 (60.0)       |         |
| Clinical data                        |              |                |         |
| APACHE II score, median (IQR)        | 12.0 (8.0-15.2) | 12.0 (10.0-16.0) | 0.716   |
| SAPS II score, median (IQR)          | 41.0 (32.2-47.5) | 46.0 (37.0-51.0) | 0.262   |
| Glasgow coma scale, median (IQR)     | 10.0 (8.0-11.0) | 10.0 (8.0-11.0) | 0.950   |
| Temperature (°C), median (IQR)       | 37.2 (26.7-37.8) | 37.6 (36.8-38.0) | 0.496   |
| Systolic blood pressure (mmHg), median (IQR) | 110.0 (93.7-132.5) | 100.0 (85.0-120.0) | 0.607   |
| Mean arterial pressure (mmHg), median (IQR) | 80.0 (70.0-96.2) | 82.0 (72.0-98.0) | 0.852   |
| PaO2/FiO2, median (IQR)              | 188.5 (139.5-214.0) | 197.0 (145.0-214.0) | 0.973   |
| FiO2, median (IQR)                   | 75.0 (60.0-85.0) | 75.0 (60.0-85.0) | 0.889   |
| pH, median (IQR)                     | 7.41 (7.38-7.43) | 7.40 (7.28-7.43) | 0.465   |
| Heart rate, median (IQR)             | 83.0 (60.0-103.5) | 78.0 (64.0-103.0) | 0.739   |
| Respiratory rate, median (IQR)       | 17.0 (13.0-21.0) | 16.0 (11.0-22.0) | 0.834   |
| Urinary output (mL/day), median (IQR) | 1043 (721.0-1208.0) | 963.0 (794.0-1175.0) | 0.768   |
| Laboratories                         |              |                |         |
| Sodium (mEq/L), median (IQR)         | 139.0 (132.0-144.2) | 142.0 (132.0-149.0) | 0.685   |
| Potassium (mEq/L), median (IQR)      | 3.8 (3.2-4.9) | 4.2 (3.6-5.0) | 0.506   |
| Creatinine (mg/dL), median (IQR)     | 1.1 (0.9-1.6) | 1.2 (0.9-1.5) | 0.779   |
| Hematocrit (%), median (IQR)         | 41.0 (33.0-47.2) | 36.0 (29.0-43.0) | 0.216   |
| Leucocytes (×10⁹ cells/mm³), median (IQR) | 10.5 (6.2-14.7) | 11.4 (5.7-15.3) | 0.838   |
| BUN (mg/dL), median (IQR)            | 26.0 (14.2-64.7) | 28.0 (16.0-59.0) | 0.861   |
| Bicarbonate (mEq/L), median (IQR)    | 19.0 (16.7-21.0) | 19.0 (16.0-22.0) | 0.629   |
| Total bilirubin (mg/dL), median (IQR) | 4.1 (0.9-4.9) | 3.8 (1.9-5.2) | 0.809   |
| Outcome                              |              |                |         |
| In-hospital mortality, n (%)         | 3 (16.67)    | 1 (6.6)        | *       |

APACHE: chronic health evaluation; SAPS: simplified acute physiology score; IQR: interquartile range.

including isolates form all kinds of specimens) were analyzed by PFGE (89 A. baumannii and 49 K. pneumoniae), and 22 distinct PFGE patterns were observed for K. pneumoniae and 41 for A. baumannii. Similarity percentages ranged from 75% to 100%.

For A. baumannii, 12 clones were detected (Fig. 1, clones A-L), with predominant clone A detected in nostrils, retro auricular, and antecubital fossae of 3 patients, as well as on Tables, bed rails, and ventilator surfaces. For K. pneumoniae, nine clones were detected (Fig. 2, clones A-I). K. pneumoniae isolates were recovered from the rectum, nostrils, and retro auricular fossae of 2 patients.

### DISCUSSION

In this study, we assessed the effect of bathing patients daily with CHG on colonization on patients, in their environments, and among healthcare personnel caring for them. Our results showed that CHG baths significantly decreased the amount of A. baumannii in the nearby surrounding areas of patients, and this may reduce the risk of HAIs.

A. baumannii is one of the most important causative agents of VAP (12), and the reduction of this bacterial species may lead to less VAP cases. In our study, HAIs were more common in patients with a placebo
### Table 2. Distribution of *K. pneumoniae*, *A. baumannii* and *P. aeruginosa* isolates among patients and environmental surfaces

|                      | Day | 0   | 3   | 10  | 0 vs. 3 | 0 vs. 10 | 3 vs. 10 | 0 vs. 3 vs. 10 |
|----------------------|-----|-----|-----|-----|---------|----------|----------|----------------|
| **K. pneumoniae**    |     |     |     |     |         |          |          |                |
| Tables (n)           | 1   | 0   | 2   | 1   | 1.000   | 1.000    | 0.583    | 1.000         |
|                      | 2   | 0   | 5   | 1   | NE      | NE       | NE       | NE            |
| Bedrails (n)         | 1   | 0   | 0   | 0   | NE      | NE       | NE       | NE            |
|                      | 2   | 0   | 1   | 2   | NE      | NE       | NE       | NE            |
| Ventilators (n)      | 1   | 2   | 6   | 2   | 0.594   | 0.628    | 0.685    | 0.202         |
|                      | 2   | 2   | 4   | 1   | NE      | NE       | NE       | NE            |
| Nasal (n)            | 1   | 3   | 4   | 2   | 0.689   | 0.500    | 0.500    | 0.181         |
|                      | 2   | 2   | 3   | 3   | NE      | NE       | NE       | NE            |
| Retro auricular (n)  | 1   | 1   | 0   | 2   | 0.400   | 0.714    | 0.300    | 0.660         |
|                      | 2   | 1   | 3   | 3   | NE      | NE       | NE       | NE            |
| Cubital fossa (n)    | 1   | 0   | 0   | 0   | NE      | NE       | NE       | NE            |
|                      | 2   | 0   | 2   | 4   | NE      | NE       | NE       | NE            |
| Anorectal (n)        | 1   | 2   | 5   | 2   | 0.296   | 0.651    | 0.412    | 0.370         |
|                      | 2   | 4   | 3   | 3   | NE      | NE       | NE       | NE            |
| All environmental surfaces (n) | 1   | 2   | 8   | 3   | 0.631   | 0.651    | 0.648    | 0.582         |
|                      | 2   | 2   | 10  | 4   | NE      | NE       | NE       | NE            |
| All corporal surfaces (n) | 1   | 6   | 9   | 6   | 0.613   | 0.320    | 0.298    | 0.431         |
|                      | 2   | 7   | 11  | 13  | NE      | NE       | NE       | NE            |
| **A. baumannii**     |     |     |     |     |         |          |          |                |
| Tables (n)           | 1   | 2   | 4   | 5   | 0.666   | 0.500    | 0.500    | 0.537         |
|                      | 2   | 1   | 3   | 6   | NE      | NE       | NE       | NE            |
| Bedrails (n)         | 1   | 4   | 2   | 3   | 0.156   | 0.181    | 0.617    | 0.113         |
|                      | 2   | 2   | 6   | 7   | NE      | NE       | NE       | NE            |
| Ventilators (n)      | 1   | 5   | 7   | 3   | 0.267   | 0.157    | 0.418    | 0.169         |
|                      | 2   | 2   | 8   | 6   | NE      | NE       | NE       | NE            |
| Nasal (n)            | 1   | 1   | 1   | 3   | 0.523   | 0.618    | 0.545    | 0.541         |
|                      | 2   | 1   | 4   | 6   | NE      | NE       | NE       | NE            |
| Retroauricular (n)   | 1   | 3   | 3   | 1   | 0.484   | 0.666    | 0.706    | 0.474         |
|                      | 2   | 4   | 7   | 2   | NE      | NE       | NE       | NE            |
| Cubital fossa (n)    | 1   | 2   | 3   | 4   | 0.713   | 0.383    | 0.328    | 0.523         |
|                      | 2   | 4   | 6   | 3   | NE      | NE       | NE       | NE            |
| Anorectal (n)        | 1   | 1   | 1   | 1   | 0.642   | 0.700    | 0.523    | 0.708         |
|                      | 2   | 2   | 4   | 1   | NE      | NE       | NE       | NE            |
| All environmental surfaces (n) | 1   | 11  | 13  | 11  | 0.090   | 0.038    | 0.396    | 0.038         |
|                      | 2   | 5   | 17  | 19  | NE      | NE       | NE       | NE            |
| All corporal surfaces | 1   | 7   | 8   | 9   | 0.311   | 0.530    | 0.205    | 0.461         |
|                      | 2   | 11  | 21  | 12  | NE      | NE       | NE       | NE            |
| **P. aeruginosa**    |     |     |     |     |         |          |          |                |
| Tables (n)           | 1   | 0   | 1   | 0   | 1.000   | NE       | 1.000    | 1.000         |
|                      | 2   | 0   | 0   | 0   | NE      | NE       | NE       | NE            |
| Bedrails (n)         | 1   | 0   | 0   | 1   | NE      | 1.000    | 1.000    | 1.000         |
|                      | 2   | 0   | 0   | 0   | NE      | NE       | NE       | NE            |
| Ventilators (n)      | 1   | 0   | 3   | 1   | 1.000   | 1.000    | 0.800    | 1.000         |
|                      | 2   | 0   | 1   | 0   | NE      | NE       | NE       | NE            |
| Nasal (n)            | 1   | 0   | 1   | 1   | 1.000   | 1.000    | 0.700    | 1.000         |
|                      | 2   | 0   | 1   | 2   | NE      | NE       | NE       | NE            |
Table 2. Continuing...

| Substrate                                      | 1   | 0   | 0   | 1   | 1.000 | 1.000 | 0.500 | 1.000 |
|------------------------------------------------|-----|-----|-----|-----|-------|-------|-------|-------|
| Retroauricular (n)                             | 2   | 0   | 1   | 0   |       |       |       |       |
| Cubital fossa (n)                              | 1   | 0   | 2   | 1   | 1.000 | 1.000 | 1.000 | 1.000 |
| Anorectal (n)                                  | 2   | 0   | 0   | 0   |       |       |       |       |
| All environmental surfaces (n)                 | 1   | 0   | 1   | 0   | 1.000 | 1.000 | 0.333 | 1.000 |
| All corporal surfaces                          | 2   | 0   | 0   | 2   |       |       |       |       |
| All species                                    | 1   | 0   | 4   | 2   | 1.000 | 1.000 | 0.714 | 1.000 |
| Tables                                         | 2   | 0   | 1   | 0   |       |       |       |       |
| Bedrails                                       | 1   | 2   | 7   | 6   | 0.500 | 0.500 | 0.637 | 0.475 |
| Ventilators                                    | 2   | 1   | 8   | 7   |       |       |       |       |
| Nasal                                          | 1   | 4   | 2   | 4   | 0.118 | 0.165 | 0.523 | 0.097 |
| Retrosauricular                                | 2   | 2   | 7   | 9   |       |       |       |       |
| Cubital Fossa                                  | 1   | 7   | 16  | 6   | 0.453 | 0.265 | 0.333 | 0.346 |
| Anorectal                                      | 2   | 4   | 13  | 8   |       |       |       |       |
| All environmental surfaces (n)                 | 1   | 4   | 6   | 6   | 0.438 | 0.296 | 0.475 | 0.316 |
| All corporal surfaces                          | 2   | 3   | 8   | 11  |       |       |       |       |

(80%) than in patients with CHG bath (55%), and the most frequent pathogen associated with HAI was A. baumannii (n=11) and in all cases was associated to VAP.

Multiple studies have demonstrated that daily bathing with CHG is a cost-benefit approach in terms of nursing time that may reduce infections caused by Gram-negative bacteria, including A. baumannii (13, 14). However, two meta-analyses have shown the opposite. The first included 34,895 patients and demonstrated that the CHG bath does not lower the risk of Gram-negative infections (including Acinetobacter spp.) in the ICU compared with traditional bathing method \( (p = 0.24) \) (15). The second study included 22,850 patients and showed similar results (16).

It has been reported that exposure to sublethal CHG levels may enhance resistance to this antiseptic. Indeed, a pan-resistant isolate of A. baumannii that was able to grow in 1% CHG has been reported (17). For this reason, it is essential to survey the compliance with CHG bathing to reduce the exposure to suboptimal concentrations of CHG and the risk of acquiring CHG resistance. In our study, the compliance was 100%; thus, a low generation of resistance was expected.

Our findings show a lower number of isolates from patient bedrails was detected when patients were bathed with CHG, and although this result was not statistically significant \( (p = 0.097) \), it underscores that bedrails deserve special attention when cleaning and disinfecting because patients and HCWs frequently touch it.

Concerning Gram-positive bacteria, CHG has been reported to prevent colonization by Enterococcus spp. resistant to vancomycin in critically ill patients (7, 8). In our study, Enterococcus spp. was isolated in
Fig. 1. Clonal relatedness of selected A. baumannii isolates. Tenover criteria were used for interpretation using the Jaccard coefficient
Fig. 2. Clonal relatedness of selected *K. pneumoniae* isolates. Tenover criteria were used for interpretation using the Jaccard coefficient.
several patients; however, no significant differences were detected.

Our study has some limitations. We did not evaluate the skin concentrations of CHG after bathing to ensure compliance. In addition, minimal inhibitory concentrations to CHG to evaluate the potential generation of resistance was not determined.

In conclusion, our data support that bathing patients with CHG decreases A. baumannii surviving on environmental surfaces surrounding of critically ill patients and that the bedrails of patients deserve special attention when cleaning and disinfecting patients’ beds.

ACKNOWLEDGEMENTS

We thank to Myriam Zamora, Andrea López, and Lucy Acevedo for assistance in technical support. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES

1. Kleven RM, Edwards JR, Gaynes RP. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis 2008; 47: 927-930.
2. Stone PW, Larson E, Kawar LN, National Nosocomial Infections Surveillance System. A systematic audit of economic evidence linking nosocomial infections and infection control interventions: 1990-2000. Am J Infect Control 2002; 30: 145-152.
3. Eggimann P, Pittet D. Infection control in the ICU. Chest 2001; 120: 2059-2093.
4. Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 2013; 11: 297-308.
5. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ES-KAPE! An update from the infectious diseases society of America. Clin Infect Dis 2009; 48: 1-12.
6. Pallotta C, Fiorio M, De Angelis V, Ripoli A, Franciosini E, Quondam Girolamo L, et al. Daily bathing with 4% chlorhexidine gluconate in intensive care settings: a randomized controlled trial. Clin Microbiol Infect 2019; 25: 705-710.
7. Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA, et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368: 533-542.
8. Climo MW, Sepkowitz KA, Zuccotti G, Fraser VJ, Warren DK, Perl TM, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 2009; 37: 1858-1865.
9. Cassir N, Thomas G, Hraiech S, Brunet J, Fournier PE, La Scola B, et al. Chlorhexidine daily bathing: impact on health care-associated infections caused by gram-negative bacteria. Am J Infect Control 2015; 43: 640-643.
10. Cruz-López F, Villarreal-Treviño L, Morfin-Otero R, Martínez-Meléndez A, Camacho-Ortiz A, Rodríguez-Noriega E, et al. Dynamics of colonization in patients with health care associated infections at step-down care units from a tertiary care hospital in Mexico. Am J Infect Control 2020; 48: 1329-1335.
11. Mendoza-Olazarán S, Camacho-Ortiz A, Martínez-Reséndez MF, Llaca-Díaz JM, Pérez-Rodríguez E, Garza-González E. Influence of whole-body washing of critically ill patients with chlorhexidine on Acinetobacter baumannii isolates. Am J Infect Control 2014; 42: 874-878.
12. Tsioctis C, Kritsotakis EI, Karageorgos SA, Stratakou S, Psarologakis C, Kokkini S, et al. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. Int J Antimicrob Agents 2016; 48: 492-497.
13. Martínez-Reséndez MF, Garza-González E, Mendoza-Olazarán S, Herrera-Guerra A, Rodríguez-López JM, Pérez-Rodríguez E, et al. Impact of daily chlorhexidine baths and hand hygiene compliance on nosocomial infection rates in critically ill patients. Am J Infect Control 2014; 42: 713-717.
14. Antunes LC, Visca P, Towner KJ. Acinetobacter baumannii: evolution of a global pathogen. Pathog Dis 2014; 71: 292-301.
15. Patel A, Parikh P, Dunn AN, Otter JA, Thota P, Fraser TG, et al. Effectiveness of daily chlorhexidine bathing for reducing gram-negative infections: A meta-analysis. Infect Control Hosp Epidemiol 2019; 40: 392-399.
16. Afonso E, Blot K, Blot S. Prevention of hospital-acquired bloodstream infections through chlorhexidine gluconate-impregnated washcloth bathing in intensive care units: a systematic review and meta-analysis of randomised crossover trials. Euro Surveill 2016; 21: 30400.
17. Brooks SE, Walczak MA, Hameed R, Coonan P. Chlorhexidine resistance in antibiotic-resistant bacteria isolated from the surfaces of dispensers of soap containing chlorhexidine. Infect Control Hosp Epidemiol 2002; 23: 692-695.